Literature DB >> 20384870

Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation.

M Sioud1, A Mobergslien, A Boudabous, Y Fløisand.   

Abstract

Human bone marrow-derived mesenchymal stem cells (MSC) are multipotent non-hematopoietic progenitors that have regulatory activity on immune cells. NOD- and Toll-like receptors (NLR, TLR) have several roles in immunity, including those relevant to pathogen recognition and shaping the course of immune responses by controlling gene expression. We have shown that these innate immune receptors are expressed by hematopoietic CD34+ progenitors and MSC. To uncover genes critical in MSC function, first we have used microarray to screen for potential transcripts whose levels are altered in response to NOD-1 and TLR-2 activation, and second we validated some candidate genes using real-time RT-PCR, Western blots and cellular assays. Amongst the altered genes, galectin-3 was upregulated at both mRNA and protein levels in response to TLR-2 activation. Interestingly, MSC secreted galectin-3, a protein known to modulate T-cell proliferation, gene expression, cell adhesion and migration. Knockdown of galectin-3 in MSC using small interfering RNA (siRNA) reduced the immunosuppressive effect of MSC on mixed lymphocyte cultures when compared to cells treated with an irrelevant siRNA (P < 0.05). Collectively, the data emphasize a new role of galectin-3 in the immunomodulatory function of MSC and indicate that NOD signalling pathway is also functional in these cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20384870     DOI: 10.1111/j.1365-3083.2010.02378.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  49 in total

Review 1.  Multipotent mesenchymal stromal cells and the innate immune system.

Authors:  Katarina Le Blanc; Dimitrios Mougiakakos
Journal:  Nat Rev Immunol       Date:  2012-04-25       Impact factor: 53.106

Review 2.  Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes.

Authors:  Rita Anzalone; Melania Lo Iacono; Tiziana Loria; Antonino Di Stefano; Pantaleo Giannuzzi; Felicia Farina; Giampiero La Rocca
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

Review 3.  Mesenchymal stem cells in the pathogenesis and therapy of breast cancer.

Authors:  Christelle P El-Haibi; Antoine E Karnoub
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-12-21       Impact factor: 2.673

Review 4.  Mesenchymal stromal cells in renal transplantation: opportunities and challenges.

Authors:  Federica Casiraghi; Norberto Perico; Monica Cortinovis; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2016-02-08       Impact factor: 28.314

Review 5.  Mesenchymal stem cells: a friend or foe in immune-mediated diseases.

Authors:  Marina Gazdic; Vladislav Volarevic; Nebojsa Arsenijevic; Miodrag Stojkovic
Journal:  Stem Cell Rev Rep       Date:  2015-04       Impact factor: 5.739

Review 6.  Secretion of immunoregulatory cytokines by mesenchymal stem cells.

Authors:  Dobroslav Kyurkchiev; Ivan Bochev; Ekaterina Ivanova-Todorova; Milena Mourdjeva; Tsvetelina Oreshkova; Kalina Belemezova; Stanimir Kyurkchiev
Journal:  World J Stem Cells       Date:  2014-11-26       Impact factor: 5.326

7.  Comparative analysis of human mesenchymal stem cells from fetal-bone marrow, adipose tissue, and Warton's jelly as sources of cell immunomodulatory therapy.

Authors:  Qiushi Wang; Qiaoni Yang; Zhe Wang; Haixia Tong; Liangyan Ma; Yi Zhang; Fengping Shan; Yiming Meng; Zhengwei Yuan
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

8.  A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma.

Authors:  Ayaka M Silverman; Rie Nakata; Hiroyuki Shimada; Richard Sposto; Yves A DeClerck
Journal:  Cancer Res       Date:  2012-03-02       Impact factor: 12.701

Review 9.  Immunomodulatory properties and therapeutic application of mesenchymal stem cells.

Authors:  M Shi; Z-W Liu; F-S Wang
Journal:  Clin Exp Immunol       Date:  2011-02-24       Impact factor: 4.330

Review 10.  Extrinsic and Intrinsic Mechanisms by Which Mesenchymal Stem Cells Suppress the Immune System.

Authors:  Vivien J Coulson-Thomas; Yvette M Coulson-Thomas; Tarsis F Gesteira; Winston W-Y Kao
Journal:  Ocul Surf       Date:  2016-01-12       Impact factor: 5.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.